Ivabradina Genepharm

Ivabradine, the active ingredient in Ivabradina Genepharm, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate without affecting contractility and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Genepharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Ivabradina Genepharm acts on the cardiac If current to manage conditions characterized by excessive heart rate. - Chronic stable angina: reduces frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalizations. - Coronary artery disease: helps control heart rate and relieve ischemic symptoms.

Ivabradina Genepharm may cause a range of adverse reactions, which are classified by frequency and severity. Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below 50 beats per minute. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness. Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Hepatic enzyme elevation.

Before prescribing Ivabradina Genepharm, clinicians should consider several precautionary measures to ensure patient safety. - Cardiac monitoring: assess resting heart rate and ECG before initiating therapy. - Concomitant beta‑blockers: avoid combined use unless closely supervised to prevent excessive bradycardia. - Severe hepatic impairment: use with caution or avoid, as drug clearance may be reduced. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Ivabradina Genepharm can interact with other medicines that affect its metabolism or heart rate. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure. - Other heart‑rate‑lowering agents (beta‑blockers, digoxin): may cause severe bradycardia. - CYP3A4 inducers (e.g., rifampicin): may reduce ivabradine efficacy. Moderate Interactions (Monitor Closely): - Calcium channel blockers (verapamil, diltiazem): may raise plasma levels modestly. - Antihypertensives: may enhance hypotensive effect.